Effect of ABCB1 gene polymorphism on warfarin dose and construction and verification of warfarin dose model

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900025879

Enrollment

Unknown

Registered

2019-09-12

Start date

2019-09-01

Completion date

Unknown

Last updated

2019-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cardiac valve disease

Interventions

Case Series:Warfarin

Eligibility

Sex/Gender

All

Age

18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Valve replacement/repair (valvular annulus) operation at Nanjing Gulou Hospital during September 2019 to December 2019; 2. Warfarin anticoagulant therapy for at least 3 months; 3. Aged 18 years and older (inclusive).

Exclusion criteria

Exclusion criteria: 1. Patients with severe thyroid function, liver function, renal dysfunction, malignancy, blood system disease or pregnancy; 2. Patients taking other anticoagulant drugs during warfarin; 3. Patients who are allergic to warfarin or difficult to tolerate warfarin.

Design outcomes

Primary

Measure	Time frame
PT/INR;	—

Countries

China

Contacts

Public ContactXu Hang

Nanjing Drum Tower Hospital

m15175030903@163.com+86 13022519537

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026